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Abstract: Diets high in glycemic index (GI) and glycemic load (GL) have been related to an increased
risk of selected cancers, but additional quantification is required. We updated a systematic review
and meta-analysis published in 2015 to May 2019 to provide quantitative information on GI/GL
and cancer risk. Relative risks (RR) and the corresponding 95 % confidence intervals (CI) for the
highest versus the lowest categories of GI and GL were extracted from selected studies and pooled
using random-effects models. Twenty reports (>22,000 cancer cases) have become available after
January 2015, and 15 were added to the meta-analyses by cancer sites, which considered a total of
88 investigations. The five additional reports were reviewed, but not included in the meta-analyses,
since data were inadequate to be pooled. For hormone-related cancers, summary RRs for the highest
versus lowest GI and GL intakes were moderately increased. They ranged from 1.04 (breast) to 1.12
(endometrium) for GI and from 1.03 (prostate) to 1.22 (ovary) for GL, of borderline significance.
High GI was associated with small increased risks of colorectal (summary RR for GI: 1.20, 95% CI,
1.07–1.34—GL: 1.09, 95% CI, 0.97–1.22, 19 studies), bladder (GI: 1.25, 95% CI, 1.11–1.41—GL: 1.10,
95% CI, 0.85–1.42, four studies) and kidney cancers (GI: 1.16, 95% CI, 1.02–1.32—GL: 1.14, 95% CI,
0.81–1.60, five studies). GL was not significantly related to those cancer sites. Stomach, prostate
and lung cancers were not associated with GI and GL. The present analysis, based on an updated
comprehensive evaluation of the epidemiological literature, indicates moderate unfavorable effects of
high versus low GI on colorectal, and possibly bladder and kidney cancers, and a possible moderate
positive association between GL and endometrial cancer.
Keywords: cancer; glycemic index; glycemic load; review; risk
1. Introduction
The glycemic index (GI) is an index of carbohydrate foods which indicates how quickly the
food causes an increase in blood glucose levels [1]. High GI foods have fast-release carbohydrates
and higher blood glucose concentrations, leading to increased insulin secretion. Low GI foods are
digested, absorbed and metabolized more slowly, thus, resulting in a more gradual rise in blood
glucose. The glycemic load (GL) is the product of GI and the total available carbohydrate content in a
given amount of food. It reflects both the quality (i.e., GI) and the quantity of carbohydrates [2].
Postprandial glycaemia, and consequently dietary GI and GL have been related to diabetes,
coronary heart disease (CHD) and obesity [3–5].
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A possible role in the development of selected cancers has been also suggested [6], but the
evidence is yet weak [7]. Long-term consumption of a high GI/GL diet results in chronically high blood
glucose, and hence, to chronically elevated insulin concentration. Insulin increases bioactive IGF-1,
which promote cancer development by inhibiting apoptosis and stimulating cell proliferation [8,9].
In addition, hyperglycemia, insulin resistance, diabetes and obesity, which are linked to glucose
metabolism, may affect the risk of cancer [4,10–12].
In 2015, we systematically reviewed data from 75 epidemiological reports addressing the
association between dietary GI and GL and the risk of cancer, for over 147,000 cancer cases [13].
Seventy-two studies were included in the meta-analyses by cancer sites. The summary relative risks
(RR) of hormone-related cancers for the highest versus the lowest study-specific category ranged from
1.05 (95% confidence interval, CI, 0.99–1.11, breast cancer) to 1.13 (95% CI, 0.98–1.32, endometrial cancer)
for GI, and from 1.04 (95% CI, 0.91–1.18, prostate cancer) to 1.19 (95% CI, 0.85–1.68, ovarian cancer) for
GL. A significantly increased colorectal cancer risk emerged for high GI (summary RR = 1.16, 95% CI,
1.07–1.25). Other summary RRs were not significantly above unity.
After that review, 20 reports [14–33] have been published, accounting for 23 distinct original
studies and almost 22,000 additional cancer cases. These included the EPIC-Italy cohort investigating
multiple cancer sites [26], the Framingham Offspring cohort on adiposity-related cancers [29], a pooled
analysis of two studies on esophageal and gastric cardia adenocarcinoma [24], three studies on
colorectal cancer [17,30,31], one combined analysis of two North European cohorts on cancer of the
biliary tract [19], two studies on lung cancer [22,25] (including a combined analysis of two Asian
cohorts [25]), one on melanoma [23], four on breast cancer [14–16,32] (including the update to 2011 of
the Nurses’ Health Study II (NHSII) [16]), two on endometrial cancer [20,33], one on ovarian cancer [21],
one on bladder cancer [28], one on kidney cancer [27], and one on thyroid cancer [18].
A few meta-analyses have recently reported on GI/GL and a single cancer [34–39], but no study
has provided an updated comprehensive quantification of the association of GI/GL with a wide range
of cancer types in a single report.
Given the new original data, we updated our systematic review and meta-analysis [13] to derive
a more precise estimation of the associations. Specifically, we reviewed the most recent (up to May
2019) epidemiological data on the association between dietary GI and GL and cancer risk, updated
summary RRs for stomach, colorectal, pancreatic, breast, endometrial, ovarian and prostate cancers
and addressed issues of heterogeneity and complexities of interpretation [40]. Moreover, we calculated
meta-analytic estimates for kidney, and for the first time, lung and bladder neoplasms.
2. Materials and Methods
2.1. Search Strategy and Selection Criteria
We conducted a systematic review and a series of meta-analyses on dietary GI and dietary GL and
cancer risk following recognized reporting guidelines [41]. We included relevant studies selected in our
prior systematic review and meta-analysis on GI/GL intake and cancer risk (search up to January 2015 [13]),
and updated the search using the same search strategy through May 2019. Briefly, the following string was
used in Medline/Pubmed, with no language or other restriction: “((cancer) OR (neoplasm) OR (carcinoma))
AND ((glycemic index) OR (glycemic load) OR (glycaemic index) OR (glycaemic load))”. The electronic
search was supplemented by hand searching of references of the selected publications and previous reviews.
We selected original cohort or case-control studies that assessed the association between dietary GI
and/or GL intake and the incidence of or mortality from a specific cancer (Table 1). Studies analyzing
cancer overall were excluded [42]. To be included in the quantitative meta-analyses, studies had to report
the estimates of the RRs (i.e., odds ratios, ORs, or RRs, or hazard ratios, HRs) and the corresponding 95%
CI for categories of GI/GL intake, or information needed for their calculation; studies providing only the
RR for the increment of one unit of GI/GL were reviewed, but not considered in the meta-analyses [32,43].
We conducted meta-analyses for cancer sites investigated in at least four studies.
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Table 1. Main characteristics of the studies included in the systematic review.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Li 2017 [24]
(M + W)
US
Multicenter
Study (1)
L.A.
Multi-Ethnic
study (2)
EA, GCA
CC, pb
USA,
in (1): 1993-1995
in (2): 1992-1997
500 EA
529 GCA 2027
in (1): Validated
104-items FFQ
in (2): validated
124-items FFQ;
not specified
EA
OR: 1.58
(1.13–2.21)
V vs. I
study-specific
quintile
GCA
OR: 1.21
(0.88–1.67)
V vs. I
study-specific
quintile
EA
OR: 0.81
(0.51–1.29)
V vs. I
study-specific
quintile
GCA
OR: 0.86
(0.55–1.35)
V vs. I
study-specific
quintile
Age, sex, study, fruit
and vegetables,
smoking, GERD,
energy, BMI (only for
GL)
Haluszka
2019 [30]
(M + W)
CRC
CC, pb
Argentina
2008-2016
161 331
validated
127-items FFQ;
white bread
OR: 1.08
(0.61–1.90)
> 82.5 vs.
<77.2
III vs. I tertile
OR: 1.64
(1.16–2.34)
>298.7 vs.
<200.4
III vs. I tertile
Age, sex,
socio-economic status,
urbanization, BMI,
smoking, analgesic use,
family history,
Huang 2018
[31]
(M + W)
CRC
CC, hb and pb
China,
2010-2017
1944 2027(1168 hb, 859 pb)
validated
81-items FFQ;
glucose
OR: 3.10
(2.51–3.85)
>69.8 vs.
<64.3
IV vs. I
quartile
OR: 1.14
(0.94–1.39)
>187.2 vs.
<134.4
IV vs. I
quartile
Age, sex, marital status,
residence, education,
occupation, income,
smoking, passive
smoking, alcohol,
family history of cancer,
occupational physical
activity, household and
leisure-time activities,
energy
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Abe 2016
[17]
JPHC Study
(M, W)
CRC
Cohort
Japan,
1995/1999–2010
average FU: 12.5 years
1468 73,501 pr919,276 py
validated
128-items FFQ;
not specified
RR, M: 0.92
(9.73–1.14)
65.77-78.46 vs.
28.12-59.10
IV vs. I
quartile
RR, W: 0.97
(0.73–1.30)
64.05-80.19 vs.
14.25-57.57
IV vs. I
quartile
RR, M: 0.79
(0.58–1.08)
IV vs. I
quartile
RR, W: 0.82
(0.55–1.24)
IV vs. I
quartile
Stratified by sex and
adjusted for age, area,
alcohol, smoking, BMI,
MET, history of
diabetes, colorectal
screening, calcium,
magnesium, vitamin B6,
vitamin B12, folate,
vitamin D, n-3 PUFA,
fiber, red meat, and for
women only,
menopausal status and
use of exogenous
female hormones.
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Larsson
2016 [19]
SMC and
CSM
(M+W)
Biliary tract
Cohort
Sweden,
1998–2012
mean FU: 13.3 years
163 #
76,014 pr
1,010,777 py
validated
96-items FFQ;
white bread
Total
extrahepatic
BTC (n = 140):
RR: 2.12
(1.25–3.58)
Gallbladder
(n = 77):
RR: 1.58
(0.81–3.08)
Intrahepatic
BTC (n = 23)
RR: 1.47
(0.54–3.97)
IV (median:
88 in M and
80 in W) vs. I
(median: 73
in M and 69
in W) quartile
Total
extrahepatic
BTC (n = 140):
RR: 1.63
(1.01–2.63)
Gallbladder
(n = 77):
RR: 2.14
(1.06–4.33)
Intrahepatic
BTC (n = 23)
RR: 3.46
(1.22–9.84)
M: >213 vs.
<177
W: >202 vs.
<166
IV vs. I
(sex-specific)
quartile
Age, sex, education,
smoking, BMI, diabetes,
energy
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Sun 2018
[25]
(M, W)
SWHS and
SMHS
Lung
Cohort
Shanghai,
1997/2000–2013 in
SWHS
2002/2006–2013 in
SMHS
average FU: 14.8 years
in SWHS and 9.3 years
in SMHS
1312
(649 in
SWHS
and 663
in
SMHS)
130,852 pr
1.612,703 py
SWHS:
validated
77-items FFQ
SMHS:
validated
81-items FFQ;
not reported
RR, W
(SWHS): 1.16
(0.92–1.47)
IV (median
76.74) vs. I
(median
63.63)
quartile
RR, M
(SMHS): 0.83
(0.67–1.03)
IV (median
77.02) vs. I
(median
64.13)
quartile
RR, W
(SWHS): 1.09
(0.86–1.37)
IV (median
144.8 g/1000
kcal/d) vs. I
(median 97.72
g/1000 kcal/d)
quartile
RR, M
(SMHS): 0.85
(0.68–1.05)
IV (median
143.77 g/1000
kcal/d) vs. I
(median 95.79
g/1000 kcal/d)
quartile
Age, education, income,
BMI, physical activity,
energy, smoking,
alcohol (men only),
history of lung disease,
hypertension, diabetes,
family history of cancer,
menopausal status
(women only)
Melkonian
2016 [22]
(M+W)
Lung
CC, hb
USA,
not reported
1905 2413 validated FFQ;glucose
OR: 1.49
(1.21–1.83)
V vs. I
(sex-specific)
quintile
OR: 1.16
(0.94–1.42)
V vs. I
(sex-specific)
quintile
Age, education, gender,
smoking, history of
emphysema,
pneumonia, hay fever,
family history of lung
cancer, physical activity,
BMI, energy
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Malavolti
2017 [23]
(M+W)
Melanoma
CC, pb
Italy,
2005–2006
380 719
validated
188-items FFQ;
glucose
OR: 0.88
(0.55–1.42)
V (median:
55.7) vs. I
(median:
47.7) quintile
OR: 1.35
(0.80–2.27)
V
(median:149.7)
vs. I (median:
92.0) quintile
Age, sex, residence,
education, BMI,
phototype, skin
sensitivity to sun
exposure, sunburns
history, SFA, vitamin C,
vitamin D, fiber, energy
Guerrero
2019 [32]
(W)
Breast
CC, pb
Mexico,
2007–2011
509 509
validated
133-items FFQ;
glucose
OR: 1.15
(1.09–1.23)
each unit
increment
OR: 1.00
(0.99–1.02)
each unit
increment
Age, education, energy,
saturated fats,
breastfeeding duration
Castro-Quezada
2016 [14]
PREDIMED
*
(W)
Breast
Cohort
Spain,
2003/2009–2010
median FU: 4.8 years
32
4010 pr
(postmenopausal
W)
17,757 py
validated
137-items FFQ;
glucose
RR: 1.02
(0.42–2.46)
III (mean:
60.8) vs. I
(mean: 50.8)
tertile
RR: 1.00
(0.44–2.30)
III (mean:
129.0) vs. I
(mean: 82.2)
tertile
Age, center,
intervention group,
smoking, education,
physical activity, BMI,
WHtR, family history of
cancer, age at
menopause, HRT use,
statin use, energy,
alcohol, dietary fiber,
folate
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Amadou
2015 [15]
Cáncer de la
Mamá study
(W)
Breast
CC, pb
Mexico,
2004–2007
1000 1074
validated
104-items FFQ;
glucose
OR: 0.90
(0.68–1.12)
>52.5 vs.
<46.8
IV vs. I
quartile
Premenopausal
W:
1.0 (0.67–1.5)
Postmenopausal
W:
0.80
(0.55–1.2)
OR: 1.1
(0.82–1.1)
>173 vs.
<145.8
IV vs. I
quartile
Premenopausal
W:
1.3 (0.86–1.9)
Postmenopausal
W:
0.94
(0.65–1.3)
Age, age at menarche,
SES, breastfeeding, age
at first pregnancy,
family history of breast
cancer, alcohol,
physical activity, energy,
native ancestry, BMI
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Farvid 2015
[16]
NHSII
(W)
Breast
Cohort
USA,
1991–2011
2833 90,534 pr1,725,295 py
validated
128-items FFQ;
glucose
RR: 1.03
(0.91–1.16)
V (median:
57.9) vs. I
(median:
49.7) quintile
Premenopausal
W
RR: 1.05
(0.90–1.23)
Postmenopausal
W
RR: 1.08
(0.87–1.35)
RR: 0.94
(0.83–1.06)
V (median:
149) vs. I
(median: 96)
quintile
Premenopausal
W
RR: 0.93
(0.79–1.09)
Postmenopausal
W
RR: 0.95
(0.76–1.18)
Age, race, family
history of breast cancer,
history of BBD,
smoking, height, BMI at
18 years, weight change
since age 18 years, age
at menarche, parity and
age at first birth, OC
use, alcohol, energy,
menopausal status and
age at menopause,
postmenopausal
hormone use.
Hartman
2018 [33]
CPS-II
Nutrition
Cohort
(W)
Endometrium
Cohort
USA,
1999–2013
average FU: 13.6 years
425
30,997 pr
postmenopausal
W
377,265 py
validated
152-items FFQ;
not specified
RR: 0.98
(0.74–1.29)
≥54.48 vs.
<50.43
IV vs. I
quartile
RR: 0.83
(0.62–1.11)
≥126.82 vs.
<100.47
IV vs. I
quartile
Age, smoking, age at
menarche, age at
menopause, parity,
HRT, OC, physical
activity, BMI
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Brenner
2015 [20]
(W)
Endometrium
CC, pb
Canada,
2002-2006
511 980
adapted NCI
DHQ
(validated);
not specified
Not provided
OR: 0.87
(0.52–1.46)
>114.1 vs.
≤68.7
IV vs. I
quartile
Age, parity,
menopausal status,
HRT, rural residence,
weight, waist
circumference,
comorbidity (diabetes,
hypertension,
thrombosis, pulmonary
embolism, myocardial
infarction, angina
pectoris, stroke, high
cholesterol), fiber,
energy
Qin 2016
[21]
AACES
(W)
Ovary
CC, pb
USA,
2010–2014
406 609
Block 2005 FFQ
(110 items,
validated);
glucose
OR: 1.03
(0.70–1.50)
≥54.9 vs.
≤49.9
IV vs. I
quartile
OR: 1.35
(0.93–1.97)
≥65.0 vs.
≤50.8
units/1000
kcal
IV vs. I
quartile
Age, education, region,
energy, parity, OC use,
menopausal status,
tubal ligation, family
history of
breast/ovarian cancer
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Augustin
2017 [28]
(M+W)
Bladder
CC, hb
Italy,
2003–2014
578 608
validated
78-items FFQ;
white bread
OR: 1.18
(0.83–1.67)
>83 vs. <75
IV vs. I
quartile
OR: 1.96
(1.16–3.31)
≥275 vs.
<169
IV vs. I
quartile
Age, sex, study center,
education, smoking,
alcohol, abdominal
obesity, energy
Zhu 2017
[27]
(M+W)
Kidney
CC, pb
USA,
2002–2017 (ongoing)
854 1255 validated FFQ;glucose
OR: 1.32
(0.99–1.74)
IV vs. I
(sex-specific)
quartile
OR: 1.15
(0.88–1.51)
IV vs. I
(sex-specific)
quartile
Age, sex, education,
BMI, physical activity,
smoking, hypertension,
family history, energy,
HEI-2015
Zamora-Ros
2016 [18]
EPIC
(M+W)
Thyroid
Cohort
10 European countries,
1992/2000–2006/2009
mean FU: 11 years
556 477,274 pr5,262,772 py
country-specific
validated
dietary
questionnaires;glucose
RR: 0.94
(0.73–1.20)
>58.5 vs.
<53.6
IV vs. I
(cohort-wide)
quartile
RR: 0.95
(0.74–1.24)
>69.6 vs.
<54.4
unit/1000 kcal
day
IV vs. I
(cohort-wide)
quartile
Age, sex, center, BMI,
smoking, education,
physical activity, energy,
alcohol, and for women
only, menopausal status
and type
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Makarem
2017 [29]
(M+W)
Framingham
Offspring
cohort
Adiposity-related
cancers
Cohort
USA,
1991/1995-2013
565
adiposity-related
cancers§
124
breast
157
prostate
68 CRC
3184 pr
validated
126-items FFQ;
not specified
Adiposity-related
cancers
RR: 0.95
(0.73–1.24)
>57.5 vs.
<51.9
Breast
RR: 0.90
(0.59–.37)
>56.2 vs.
<53.3
III vs. I tertile
Prostate
RR: 0.74
(0.48–1.12)
>56.4 vs.
<53.6
III vs. I tertile
CRC
RR: 1.51
(0.81–2.84)
>56.3 vs.
<53.5
III vs. I tertile
Adiposity-related
cancers
RR: 0.93
(0.58–1.49)
>169.9 vs.
<85.6
Breast
RR: 0.54
(0.26–1.09)
>136.0 vs.
<96.7 g/d
III vs. I tertile
Prostate
RR: 0.76
(0.40–1.43)
>154.4 vs.
<106.3 g/d
III vs. I tertile
CRC
RR: 1.21
(0.43–3.40)
>143.7 vs.
<100.7 g/d
III vs. I tertile
Age, sex, smoking,
alcohol, energy
Breast: additional
adjustment for
menopausal status, age
at menopause,
hormone therapy, n. of
live births.
CRC: additional
adjustment for red and
processed meat, fiber
For breast, prostate and
CRC: additional
adjustment for
education, BMI, waist
circumference, physical
activity, history of
diabetes and CVD, and
antioxidant
supplements did not
change the results.
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Table 1. Cont.
Studyˆ, Year
(Sex) Cancer Site
Study Design
Study Area and Period
of Enrolment or
Follow-Up (Years)
Cases Controls/Cohort
size
Dietary
Assessment
Method;
Reference Food
for GI/GL
RR (95% CI)
Comparison Level (Highest
vs. Lowest)
Matching and
Adjustment Factors
Glycemic
Index
Glycemic
Load
Sieri 2017
[26]
(M+W)
EPIC-Italy
Various sites
Cohort
Italy
1993/1998–2009/2010
median FU: 14.9 years
5112
cancers 45,148 pr
3 validated
FFQs;
glucose
All cancers
combined
RR: 1.06
(0.97–1.16)
V (mean:
57.4) vs. I
(mean: 50.0)
quintile
The paper
reported RRs
of 20 different
cancer sites
All cancers
combined
RR: 1.05
(0.93–1.20)
V (mean:
235.2) vs. I
(mean: 86.0)
quintile
The paper
reported RRs
of 20 different
cancer sites
Age, sex, education,
BMI, physical activity,
smoking, FFQ, alcohol,
non-alcohol energy,
fiber, saturated fat
Abbreviations: AACES, African American Cancer Epidemiology Study; BBD, benign breast disease; BMI, body mass index; BTC, biliary tract cancer; CC, case-control; CI, confidence
interval; CPS, Cancer Prevention Study; CRC, colorectum; CSM, cohort of Swedish Men; CVD, cardiovascular disease; DHQ, Diet History Questionnaire; EA: Esophageal adenocarcinoma;
EPIC, European Prospective Investigation into Cancer and nutrition; FFQ, food frequency questionnaire; FU, follow-up; GCA, gastric cardia adenocarcinoma; GERD, gastro-esophageal
reflux disease; GI, glycemic index; GL, glycemic load; hb, hospital-based; HEI, Healthy Eating Index; JPHC, Japan Public Health Center-based; HRT, hormone replacement therapy; M, men;
MET, metabolic equivalent tasks; NCI, National Cancer Institute; OC, oral contraceptives; OR, odds ratio; pb, population-based; pr, persons at risk; PREDIMED, PREvención con DIeta
MEDiterránea; py, person-years; PUFA, polyunsaturated fatty acids; RR, relative risk; SFA, saturated fatty acids; SMC, Swedish Mammography Cohort; SMHS, Shanghai Men’s Health
Study; SWHS, Shanghai Women’s Health Study; W, women; WHtR, waist-to-height ratio.ˆ Study’s name is indicated in Italic. # 140 extrahepatic (including 77 gallbladder cancers) and 23
intrahepatic biliary tract cancers. * Observational cohort of postmenopausal women at high risk of cardiovascular diseases participating in a randomized, parallel group, clinical trial (i.e.,
PREDIMED trial). § adiposity-related cancers included cancers of the gastrointestinal tract, reticuloendothelial system (blood, bone and spleen), female reproductive tracts, genitourinary
organs and the thyroid gland.
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Two reviewers independently identified eligible studies by screening titles, abstract, and when
appropriate, full-texts of articles. Any discrepancy was discussed and resolved by consensus. If there
were multiple publications from the same study population, we used data from the longest follow-up
(for cohorts) or the larger database (for case-control studies).
From each selected publication, we extracted details on study design, country, sex of the
participants, tumor site, number of enrolled subjects (cases and controls or cohort size), period of
enrolment (for case-control studies) or follow-up (for cohort studies), methods for dietary assessment
(type, number of food items, and whether it had been validated), reference food for GI/GL (white bread
or glucose), comparison levels of GI and/or GL, RR estimates (i.e., odds ratios/hazard ratios/RRs) for
the comparison between the highest versus the lowest category of GI/GL intake, and confounding
factors for which adjustment was made. When RR estimates from models with different covariates
were provided, we extracted the RRs adjusted for the largest number of confounding factors.
2.2. Statistical Analysis
We conducted quantitative meta-analyses of GI and GL intake in association with the risk of
cancer. In the current analysis, we considered cancer sites investigated in at least four studies and
for which new epidemiological data have become available after the previous review [13], i.e., breast,
endometrium, ovary and prostate among hormone-related cancers, stomach, colorectum and pancreas
among digestive tract cancers, and lung, bladder and kidney among other cancer sites. Although new
data on liver cancer have been made available from the EPIC-Italy cohort [26], we did not update
the meta-analysis on liver cancer as that data partially overlapped with those reported in 2013 by
Fedirko et al. [44], which analyzed the overall EPIC cohort.
We derived summary estimates of the RR by combining study-specific ORs or RRs or HRs for the
highest versus the lowest category of GI and GL intake using random-effects models, which account
for the heterogeneity among the RR estimates. Heterogeneity was evaluated through the χ2 test and
quantified through and the I2 statistic [45,46].
We updated subgroup analyses for breast cancer according to menopausal status and body mass
index (BMI) (<25 kg/m2 and BMI ≥ 25 kg/m2). One study showing the RR of breast cancer according to
GI and GL among women with BMI ≥ 30 kg/m2 was excluded from the subgroup analysis [14].
Publication bias was assessed through funnel plots and Egger tests [47].
All the statistical analyses were performed using the STATA software (version 14; StataCorp,
College Station, TX, USA).
3. Results
Of the 203 newly identified publications in the Medline literature (from January 2015 to May
2019), 20 were selected as original studies providing results on the association between GI and/or GL
and the risk of a specific cancer (Table 1) (for a detailed description of studies on GI/GL and cancer risk
published before January 2015, refer to Table 1—Supporting information of our previous work [13]).
Eleven reports provided results from case-control studies (including one report of a pooled analysis
of two case-control studies [24]) and nine from cohort studies (including a combined analysis of two
cohorts in Shanghai [25], a combined analysis of two Swedish cohorts [19], and a prospective analysis
based on data from the PREvención con DIeta MEDiterránea (PREDIMED trial) [14]). Two reports
gave results on a number of cancer sites [26,29]; the remaining reports were focused on a single cancer
type. These reports included a minimum of 32 [14] to a maximum of 5112 cases [26]. Eight reports
were based on studies conducted in North America, three in Central/South America, six in Europe,
and three in Asia. All studies except one [20] provided results for both GI and GL. Validated FFQs
were used in all studies to evaluate dietary habits. Most studies used glucose as reference food for
GI/GL calculation. GI/GL were categorized in quartiles in 11 reports, in quintiles in five reports and in
tertiles in three reports; one study used GI/GL as a continuous variable.
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Fifteen of the 20 newly identified reports provided data that could be added to our meta-analyses
on GI/GL and cancer risk. One publication on breast cancer providing only the RRs for the increment
of one unit of GI/GL [32], and four publications on cancers sites for which less than four studies
were available (i.e., esophagus and gastric cardia [24], biliary tract [19], melanoma [23], thyroid [18]),
were not considered in the quantitative meta-analyses. In the meta-analyses on breast cancer, the 2015
paper by Farvid et al. [16] with updated results of the NHSII cohort replaced the 2003 paper by
Cho et al. [48], which was based on a shorter follow-up and a quarter of the cases. Similarly, in the
meta-analyses on colorectal cancer, updated results from the EPIC-Italy cohort [26] replaced data from
an earlier publication on the same cohort [49]. Updated data from the EPIC-Italy cohort [26] did not
contribute to the meta-analyses on breast and endometrial cancers as the analyses already included
larger amounts of data from the overall EPIC cohort [50,51]. In addition, we retrieved one publication
on ovarian cancer not previously identified [52].
3.1. Results of the Individual Studies
3.1.1. Multiple Cancer Sites
The EPIC-Italy cohort provided results for 21 different cancer types [26]. In a median follow-up of
about 15 years, 5112 incident cancers occurred (including 441 colon, 102 rectal, 117 pancreatic, 307 lung,
1362 breast, 203 endometrial, 135 ovarian, 481 prostate, 251 bladder and 136 kidney cancers). For most
cancer sites, no association was found for either dietary GI or GL. High GI was associated with an
increased risk of colon (HR for the fifth versus first quintile: 1.48, 95% CI, 1.09–2.01) and bladder
cancer (HR: 1.51, 95% CI, 1.01–2.25), and high GL with an increased risk of colon (HR: 1.80, 95% CI,
1.18-2.74) and diabetes-related cancers (HR: 1.23, 95% CI, 1.03–1.48), but a decreased risk of rectal
cancer (HR: 0.42, 95% CI, 0.18–0.98). The Framingham Offspring cohort found no association between
GI, GL and adiposity-related cancers, based on a total of 656 incident cancers of the gastrointestinal
tract, reticuloendothelial system (blood, bone and spleen), female reproductive tracts, genitourinary
organs and the thyroid gland [29]. In analyses by cancer type, no significant associations were found
for breast, colorectal, and prostate cancers. The HRs for the third versus first tertile were 0.90 (95%
CI, 0.59–1.37) for GI and 0.54 (95% CI, 0.26–1.09) for GL for breast cancer (124 cases), 1.51 (95% CI,
0.81–2.84) for GI and 1.21 (95% CI, 0.43–3.40) for GL for colorectal cancer (68 cases), and 0.74 (95% CI,
0.48–1.12) for GI and 0.76 (95% CI, 0.40–1.43) for GL for prostate cancer (157 cases).
3.1.2. Hormone-Related Cancers
As for breast cancer, the update of the NHSII, which included 12 additional years of follow-up
and almost four times the number of cases compared to the 2003 report [48], found a null association
between GI and GL and breast cancer risk, with HRs for the fifth versus the first quintile of 1.03 (95%
CI, 0.91–1.16) for GI and 0.94 (95% CI, 0.83–1.06) for GL, based on 2833 invasive cases [16]. Similar null
results were observed in pre- (HR for GI: 1.05, HR for GL: 0.93) and post-menopause (HR for GI: 1.08,
HR for GL: 0.95), as well as among normo- (HR for GI: 1.04, HR for GL: 0.94) and over-weight women
(HR for GI: 1.12, HR for GL: 1.19, not significant). In a secondary analysis within the framework of
the PREDIMED trial, based on 32 incident cases, dietary GI and GL were not related to breast cancer
among postmenopausal women at high risk of cardiovascular diseases (HR for the third versus the first
tertile 1.02, 95% CI, 0.42–2.46 for GI and 1.00, 95% CI, 0.44–2.30 for GL) [14]. No association with breast
cancer was also reported in a Mexican population-based case-control study including 1000 women
with breast cancer, the ORs for the fourth versus the first quartile being 0.90 (95% CI, 0.68–1.2) for GI
and 1.1 (95% CI, 0.82–1.1) for GL [15]. In that study, a null association was also observed in subgroups
defined by menopausal status and BMI. A further Mexican case-control study, including 509 cases
matched 1:1 by age with 509 population controls, found a positive association between GI and breast
cancer overall (OR for 1 unit increase 1.15, 95% CI, 1.09–1.23) and luminal A, HER2+ and TN molecular
subtypes; no association emerged for GL regardless of the subtype [32].
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Two studies investigating GI/GL in relation to endometrial cancer found both an absence of
association [20,33]. The HRs were 0.98 (95% CI, 0.74–1.29) for GI and 0.83 (95% CI, 0.62–1.11) for GL for
the fourth versus first quartile in the US Cancer Prevention Study II (CPS-II) Nutrition Cohort, which
included 425 incident cases occurred during a median follow-up of about 14 years [33]. In addition,
a Canadian case-control study with over 500 cases and 980 population controls found an OR of 0.87
(95% CI, 0.52–1.49) for the fourth versus the first quartile of dietary GL, with no effect modification by
BMI [20].
As for ovarian cancer, a case-control study among African-Americans in the USA enrolling about
400 cases and 600 population controls found no association with GI (OR for the fourth versus the first
quartile 1.03, 95% CI, 0.84–1.18), but a suggestion of a positive association with GL [21]. The ORs
were 1.18 (95% CI, 1.04–1.33) per 10 units of GL/1000 kcal in the continuous analysis and 1.35 (95% CI,
0.93–1.97) for the highest versus the lowest quartile of GL when the variable was considered in
categories; in the latter analysis, however, a clear dose-risk relationship did not emerge (ORs for
subsequent quartiles: 1.16, 1.57 [significant], 1.35, p for trend = 0.05) [21].
3.1.3. Cancers of the Digestive Tract
Two case-control [30,31] and one cohort study [17] on colorectal cancer have become available after
the previous meta-analysis. The Japan Public Health Center-based prospective Study (JPHC Study)
provided, for the first time, data on GI/GL and colorectal cancer risk in a Japanese population [17].
Based on 1468 incident cases from a population of over 73,000 subjects followed for 12.5 years on
average, the JPHC study found overall non-significant results for GI, as well as GL; the HRs of colorectal
cancer for the fourth versus the first quartile were 0.92 (95% CI, 0.73–1.14) in men and 0.97 (95% CI,
0.73–1.30) in women for GI, and 0.79 (95% CI, 0.58-1.08) in men and 0.82 (95% CI, 0.55–1.24) in women
for GL. However, a non-significantly reduced risk of (proximal) colon cancer for high GL consumption
was observed in men (HRs for proximal colon cancer: 0.62, 95% CI, 0.36–1.08) and a non-significantly
reduced risk of rectal cancer for high GI (HRs 0.58, 95% CI, 0.33–1.03) and GL (HR: 0.52, 95% CI,
0.24–1.14) was found in women [17]. A Chinese case-control study, including 1944 cases and 2027
community-derived or hospital controls, reported a positive association between GI and colorectal (OR
for the fourth versus first quartile: 3.10, 95% CI, 2.51–3.85), as well as colon (1172 cases) and rectal
cancer (772 cases), similar in men and women [31]. High GL was not associated with colorectal (OR for
the fourth versus first quartile: 1.14, 95% CI, 0.94–1.35), colon or rectal cancer. However, an increased
risk of colorectal cancer for the highest versus lowest quartile of GL was found in women only (OR
1.42, 95% CI, 1.04–1.95). A case-control study from Argentina and based on 161 cases of colorectal
cancer and 331 population-based controls showed significant positive associations with GI and GL
in women only (OR for the third versus first tertile 2.12, 95% CI, 1.38–3.27 for GI, OR: 1.98, 95% CI,
1.24–3.18 for GL) [30].
3.1.4. Other Neoplasms
A pooled analysis of two US population-based case-control studies (i.e., the US Multi-Center
Study and the Los Angeles Multi-Ethnic Study), including overall 500 esophageal adenocarcinomas,
529 gastric cardia adenocarcinomas and 2027 controls, reported an increased risk of esophageal
adenocarcinoma for the fifth versus the first quintile of GI intake (OR 1.58, 95% CI, 1.13–2.21), in the
absence, however, of a clear dose-risk relationship (p for trend 0.32). Such positive association was
evident only among subjects with BMI ≥ 25 kg/m2. No relation emerged between GI and esophageal
adenocarcinoma (OR for the fifth versus the first quintile: 1.21, 95% CI, 0.88–1.67), as well as between
GL intake and esophageal (OR: 0.81, 95% CI, 0.51–1.29) and gastric cardia adenocarcinoma (OR: 0.86,
95% CI, 0.55–1.35) [24].
Dietary GI and GL were positively related to the risk of biliary tract cancer in the combined analysis
of the Swedish Mammography Cohort and cohort of Swedish Men, which included 140 extrahepatic
and 23 intrahepatic cancer cases developed from a population of over 76,000 individuals during a
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mean follow-up of 13.3 years [19]. The HRs for the fourth versus first quartile of dietary GI was
2.12 (95% CI, 1.25–3.58) for extrahepatic and 1.47 (95% CI, 0.54–3.97) for intrahepatic biliary tract
cancer; the corresponding values for GL were, respectively, 1.63 (95% CI, 1.01–2.63) and 3.46 (95% CI,
1.22–9.84) [19].
Two reports gave results on GI/GL and lung cancer [22,25]. Data from the Shanghai Women’s
and Men’s Health Studies, including 649 incident lung cancers among women and 663 among men
developed during an average follow-up of about 15 years, indicated no association of GI or GL with
lung cancer [25]. The HRs for the fourth versus the first quartile of GI was 1.16 (95% CI, 0.92–1.47)
in women and 0.83 (95% CI, 0.67–1.03) in men; the corresponding figures for GL were 1.09 (95% CI,
0.86-1.37) in women and 0.85 (95% CI, 0.68–1.05) in men. Null findings were also found in strata of
BMI, smoking, family history of cancer and menopausal status (in women). In a population-based
case-control study from USA based on 1905 incident cases and 2413 controls [22] a significant positive
association with lung cancer risk was found for GI (OR for the fifth versus the first quintile 1.49, 95% CI,
1.21–1.83, p for trend < 0.001), but not for GL (OR 1.16, 95% CI, 0.94–1.42). The positive association
with GI was more evident among never smokers (OR fifth quintile 2.25, 95% CI, 1.42–3.57) and for the
squamous cell carcinoma histologic subtype (OR 1.30, 95% CI, 1.02–1.67) [22].
An Italian population-based case-control study including 380 cases of melanoma and 719 age-
and sex-matched controls reported a positive association with GL among women (OR 2.38; 95% CI
1.25, 4.52 for the highest versus the lowest quintile, p for trend = 0.070), but not among men (OR 0.86,
95% CI, 0.47–1.57), and a lack of relation with GI in either sex [23].
A positive association between GL and bladder cancer risk was found in a case-control study
from Italy, including 578 cases and 608 hospital-controls. The risk of bladder cancer was significantly
increased from the second quartile onwards, and subjects in the fourth quartile had an approximately
doubled risk of bladder cancer compared to those in the first one (OR 1.96, 95% CI, 1.16–3.31) [28].
No association emerged with GI.
One case-control study from USA investigated renal cell carcinoma and found a positive association
for GI and an absence of association for GL [27]. Based on a total of 854 cases and 1255 population-based
controls, the ORs for the fourth versus the first quartile were 1.32 (95% CI, 0.99–1.74; p for trend = 0.026)
for GI and 1.15 (95% CI, 0.88–1.51) for GL.
An analysis based on 556 well-differentiated thyroid cancers within the EPIC cohort found overall
no association with GI (HR for the fourth versus first quartile: 0.94, 95% CI, 0.73–1.20) and GL (HR:
0.95, 95% CI, 0.74–1.24) [18]. In stratified analysis, a significant positive relation among overweight
(HR: 1.54, 95% CI, 1.05–2.28, p for trend = 0.014) and an inverse one among normoweight subjects
(HR: 0.64, 95% CI, 0.46–0.89, p for trend = 0.003) emerged with GI [18].
3.2. Update of the Summary Estimates
Overall, 88 reports were included in the meta-analyses on GI/GL and cancer risk (see Supplementary
Materials for complete bibliography references). Summary RRs of hormone-related cancers,
digestive-tract cancers and other neoplasms for the highest versus the lowest category of GI (Panel
A) and GL (Panel B) intake are presented, respectively, in Figures 1–3. There was no evidence of
publication bias according to the Egger’s tests for all cancer sites considered (data not shown).
3.2.1. Hormone-Related Cancers
Summary RR of hormone-related cancers were all above unity, but non-significant, for both GI and
GL, for all cancer sites (Figure 1). They were 1.04 (95% CI, 0.98–1.10) for GI (22 studies, 52,470 cases-Panel
A) and 1.05 (95% CI, 0.97–1.13) for GL (21 studies, 53,196 cases-Panel B) for breast cancer, 1.12 (95% CI,
0.97–1.28) for GI (11 studies, 6988 cases) and 1.12 (95% CI, 0.97–1.30) for GL (13 studies, 8468 cases)
for endometrial cancer, 1.08 (95% CI, 0.89–1.32) for GI (eight studies, 4324 cases) and 1.22 (95% CI,
0.95–1.56) for GL (eight studies, 4324 cases) for ovarian cancer, and 1.05 (95% CI, 0.95–1.16) for GI (eight
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studies, 27,294 cases) and 1.03 (95% CI, 0.91–1.16) for GL (seven studies, 27,138 cases) for prostate
cancer. Significant heterogeneity across studies was observed in all the meta-analyses.
Figure 1. Cont.
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Figure 1. Study-specific and summary relative risks (RRs) of hormone-related cancers for the highest
versus the lowest category of glycemic index (Panel A) or glycemic load intake (Panel B).
3.2.2. Digestive-Tract Cancers
There was a positive significant association between high GI intake and colorectal cancer risk.
No other significant associations were detected (Figure 2). Summary RRs were 1.09 (95% CI, 0.79-1.52)
for GI (seven studies, 3152 cases—Panel A) and 1.04 (95% CI, 0.80–1.35) for GL (seven studies,
3152 cases–Panel B) for stomach cancer, 1.20 (95% CI, 1.07–1.34) for GI (19 studies, 26,456 cases) and
1.09 (95% CI, 0.97–1.22) for GL (19 studies, 25,778 cases) for colorectal cancer, 1.09 (95% CI, 0.98–1.21)
for GI (11 studies, 3855 cases) and 0.99 (95% CI, 0.84–1.17) for GL (12 studies, 4289 cases) for pancreatic
cancer. Significant heterogeneity across studies was detected in all the meta-analyses, except for that
on GI and pancreatic cancer. In a sensitivity analysis, the summary RR of colorectal cancer according
to high GI remained statistically significant with the exclusion of each study in turn.
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Figure 2. Study-specific and summary relative risks (RRs) of digestive-tract cancers for the highest
versus the lowest category of glycemic index (Panel A) or glycemic load intake (Panel B).
3.2.3. Other Neoplasms
There was no association between high GI or GL intake and lung cancer risk, the summary RRs
being 1.11 (95% CI, 0.98–1.26) for GI (six studies, 13,385 cases) and 0.96 (95% CI, 0.87–1.06) for GL
(five studies, 12,922 cases) (Figure 3). A significant positive association was found between high
GI and bladder cancer, with a summary RR of 1.25 (95% CI, 1.11–1.41; four studies, 3339 cases);
the corresponding summary RR for GL was 1.10 (95% CI, 0.85–1.41; four studies, 3339 cases). Summary
RRs for kidney cancer were 1.16 (95% CI, 1.02–1.32) for GI (five studies, 4281 cases) and 1.14 (95% CI,
0.80–1.60) for GL (five studies, 4281 cases). Heterogeneity across studies was low-to-moderate in most
of the meta-analyses (I2 ranging from 0 to 40.5), except for those on GI and lung cancer (I2 = 68.2%)
and GL and kidney cancer (I2 = 78.6%). In sensitivity analyses, the positive association between high
GI and bladder cancer remained significant when any study was removed from the meta-analysis,
while the summary RR of kidney cancer for high GI was no longer significant with the exclusion of
each study in turn, except that by George et al. [53].
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Figure 3. Study-specific and summary relative risks (RRs) of other neoplasms for the highest versus
the lowest category of glycemic index (Panel A) or glycemic load intake (Panel B).
3.2.4. Subgroup Analyses for Breast Cancer
In subgroup analyses by menopausal status, the summary RRs of breast cancer for the highest
versus the lowest category of GI were 1.08 (95% CI, 0.96–1.21, 13 studies, p for heterogeneity = 0.043,
I2= 44.2%) for premenopausal breast cancer and 1.04 (95% CI, 0.96–1.12, 17 studies p for heterogeneity
= 0.020, I2= 45.9%) for postmenopausal breast cancer (p for heterogeneity between strata = 0.595)
(Figure 4). The corresponding figures for GL were 1.16 (95% CI, 1.00–1.34, 13 studies, p for heterogeneity
= 0.002, I2 = 62.1%) for premenopausal breast cancer and 1.05 (95% CI, 0.95–1.16, 17 studies, p for
heterogeneity < 0.001, I2 = 62.4%) for postmenopausal breast cancer (p for heterogeneity between
strata = 0.27).
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Figure 4. Study-specific and summary relative risks (RRs) of breast cancer for the highest versus the lowest category of glycemic index (A) and glycemic load (B) in
strata of menopausal status.
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Summary RRs of breast cancer in strata of BMI indicated a null association with GI and GL among
normo-weight as well as overweight women. As for GI, the RRs for the highest versus lowest intake
were 1.13 (95% CI, 0.97–1.32, six studies, p for heterogeneity = 0.132, I2 = 35.8%) for BMI < 25 kg/m2
and 0.97 (95% CI, 0.95–1.16, six studies, p for heterogeneity = 0.586, I2 = 0%) for BMI ≥ 25 kg/m2
(p for heterogeneity between strata = 0.103). Values for GL were 1.12 (95% CI, 0.94–1.34, seven studies,
p for heterogeneity = 0.003, I2 = 64.3%) for BMI < 25 kg/m2 and 0.99 (95% CI, 0.86–1.14, seven studies,
p for heterogeneity = 0.159, I2 = 31.2%) for BMI ≥ 25 kg/m2 (p for heterogeneity between strata = 0.286).
4. Discussion
The present work, based on 88 reports, represents the most updated comprehensive quantification
of the relation of GI and GL intake with cancer risk. It updates and expands a previous analysis
published in 2015, and provides meta-analytic results for kidney, and for the first time, lung and
bladder cancers. The present results largely confirm those of the previous meta-analysis [13]; summary
RRs are similar to those previously reported, but, in general, they are more precise, providing more
confidence in the results. We found significant, but small, unfavorable effects of high versus low
GI diets for colorectal, and possibly bladder and kidney cancers, and a possible modest positive
association between high GL and endometrial cancer. Most of the summary RRs were weakly and
non-significantly (or at most marginally significantly) increased, indicating no major role of GI/GL
intake in the etiology of most cancer types.
Possible biological mechanisms to explain the modest associations observed include the impact
of GI and GL on blood glucose, HbA1c, and hence, insulin and IGF-1. These may also impact on
body weight. Although body weight was allowed for in most of the analyses considered, residual
confounding may be present. However, GI and GL are correlated with other aspects of carbohydrate
quality, such as cereal fibers [54,55]. Confounding by these factors may also partly explain the
observed associations.
Our findings are broadly similar to other meta-analyses addressing the role of dietary GI, dietary
GL and cancer risk. In particular, no associations with stomach [37], prostate [7,38,39], and pancreatic
cancers [56–58] were reported by others. A meta-analysis on kidney cancer based on the same study
sample yielded essentially identical results [36], i.e., a positive, but weak, significant association with
high GI and no association with GL. Although the absence of appreciable heterogeneity among studies
supports the robustness of findings on GI and kidney cancer, the still limited number of studies and
the null association with GL need to be considered in the interpretation of findings. In addition,
the exclusion from the GI-kidney cancer meta-analysis of each study in turn—with the exception of the
study by George et al. [53]—gave non-significant summary RR estimates.
According to the World Cancer Research Fund/American Institute for Cancer Research
(WCRF/AICR), high dietary GL (but not GI) is probably a cause of endometrial cancer, while evidence
on other cancer sites, including colorectal, pancreatic, liver and breast cancers, is inconclusive [59].
The conclusion on endometrial cancer was based on a dose-response meta-analysis based on six cohort
studies published up to 2012, which estimated a significant 15% increased risk per 50 units/day of
GL. The summary RR of endometrial cancer for high versus low GL was 1.17 (95% CI, 1.00–1.37)
in our previous meta-analysis based on 11 studies [13], and 1.12 (95% CI, 0.97–1.56) in the current
update, after the inclusion of two additional studies. Although only marginally significant, such 12%
increased risk was not in contrast with the WCRF result, thought the different methods of analyses
(i.e., dose-response versus extreme quantile), inclusion criteria (e.g., only cohort versus both cohort
and case-control studies) and search updates do not allow a direct comparison. A positive association
between high GL (but not GI) and the risk of endometrial cancer was reported in other previous
meta-analyses [57,60,61], while a recent high profile publication by Reynold et al, which provided
systematic reviews and meta-analyses of prospective studies on the relationship between the most
widely studied indicators of carbohydrate quality and incidence of, and mortality from, a wide range
of non-communicable diseases, did not find any relation with GI and GL, both in dose-response and
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extreme quantile analyses [7]. In that report, high GI was associated with a marginally significant 10%
increased risk of colorectal cancer (summary RR 1.10, 95% CI, 0.99–1.22), and each 10 units/day of
GI to a 5% increased risk of borderline significance (summary RR 1.05, 95% CI, 1.00–1.10), while no
association was reported for GL [7]. Excess risks of colorectal cancer less than 10% for high versus low
GI were found in previous meta-analyses of prospective studies [57,62]. The excess risk was slightly
higher (15–20%) —but essentially comparable—in meta-analyses based on both cohort and case-control
studies [63,64], including the present one.
We found a modest nonsignificant association of GI/GL and breast cancer. Other meta-analyses
generally showed no or small (<10%) increased risks for the highest versus the lowest GI or
GL [7,34,35,57,58,65,66]. In the meta-analyses by Reynolds et al, summary RRs of breast cancer
were 1.05 (95% CI, 1.01–1.10) for high versus low GI (but 1.01, 95% CI, 0.98–1.03 for a 10 unit/day
increase) and 1.00 (95% CI, 0.95–1.06) for high versus low GL [7]. In another meta-analysis updated
to 2015, the association with GI—but not with GL—was slightly stronger in postmenopausal than
premenopausal women, but the difference was not significant; in addition, BMI did not influence the
association between GI, GL and breast cancer [34]. This is in line with the current results, showing
comparable estimates of the GI/GL-breast cancer association in pre- and post-menopausal women,
as well as in normo-weight and overweight women.
No meta-analysis has previously systematically addressed the association of GI/GL with ovarian,
lung or bladder cancers. In our study, GI and GL did not significantly influence the risk of lung and
ovarian cancer. We found a significant 25% increased risk of bladder cancer for high versus low GI
intake, and the association remained significant when excluding each study in turn; no relation was
observed for GL. Conditions related to chronic hyperinsulinemia and hyperglycemia, such as diabetes
and the metabolic syndrome, have been associated with bladder cancer [10,67]. Urinary tract infections
influence the risk of bladder cancer and may be associated with a diet promoting a large increase in
blood glucose [68]. In addition, insulin can increase the expression of epidermal growth factors and
protein kinase, and induced bladder cancer cell proliferation in in vitro studies [69,70].
Part of the different associations of dietary GI and dietary GL on selected cancer types may be
explained by differences in the underlying dietary patterns. Some studies indeed suggested that while
the overall GL of a diet is mostly associated with high-carbohydrate foods, and hence, closely correlates
to total carbohydrate intake, GI is associated not to only to high consumption of high-carbohydrate
foods, but also to low consumption of some low-carbohydrate foods (and the related nutrients),
including fruit, dairy [71,72], vegetables, and legumes [73]. Thus, dietary GI, unlike GL, may reflect
more dimensions of diet than just carbohydrates [74]. This could partly explain at least the positive
association of GI with colorectal cancer—a cancer potentially related to various aspects of diet—in the
absence of any relation with GL. In any case, in 2015, a scientific consensus statement by international
experts on carbohydrate research recognized that the GI is a valid and reproducible measure to express
the glycemic response of foods [3].
The heterogeneity in studies’ results observed in most meta-analyses may be due to several reasons,
including the dietary habits of the studied populations (i.e., low carbohydrate diets, which include
high animal proteins and fats [e.g., for North American populations] versus high carbohydrate diets
[e.g., for populations from southern Europe] [75–77]), the number and type of carbohydrate items
in the FFQs and GI values attributed to FFQ items, with the consequent different ranges of GI/GL
(particularly GL) in various studies. Moreover, studies used different methods of GI/GL categorization
in the analyses (e.g., tertiles, quartiles, quintiles); therefore, there is heterogeneity in the highest and
lowest absolute levels of GI/GL. The study design and the selection of the adjustment factors may also
contribute to the observed heterogeneity.
In epidemiologic studies, high dietary GI and GL were consistently associated with greater
risks of diabetes and CHD. When restricting our analyses on colorectal and breast cancers to large,
well-recognized cohorts which reported on GI/GL and such other health outcomes (i.e., the Swedish
Mammography Cohort and cohort of Swedish Men, the Shanghai Women’s and Men’s studies,
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the Health Professional Follow-up Study, the NHSI and NHSII, the EPIC cohort, the Women’ Health
Study and the Women’s Health Initiative), results were essentially unchanged, while heterogeneity
decreased for the GI-breast cancer (I2 = 0%, p = 0.883), GI-colorectal cancer (I2 = 9.7%, p = 0.353) and
GL-breast cancer (I2 = 6%, p = 0.384) meta-analyses, but not appreciably for the meta-analysis on GL
and colorectal cancer (I2 = 71.2%, p = 0.001).
Most studies adjusted for the most relevant confounders, i.e., BMI/physical activity, energy intake,
tobacco and social class, but some residual confounding is still possible. GI/GL are positively associated
with diabetes, and diabetes increases the risk of colorectal, pancreatic, endometrial and perhaps breast
cancer [78] (and possibly decreases the risk of prostate cancer) [79]. In addition, diabetic patients
are often advised to change their diet to lower carbohydrate intake, and this could underestimate
any positive association. Therefore, careful consideration of subjects’ diabetes condition is necessary
when examining the relation of GI and GL with diabetes-related neoplasms. In most studies on
colorectal, endometrial and prostate cancer, authors either: (1) excluded diabetics from the analyses; (2)
gave RRs adjusted for diabetes; (3) reported that adjustment for diabetes or restricting the analyses
to non-diabetic subjects did not influence the results; or (4) reported that the observed association
was independent from diabetes. However, excluding women with diabetes slightly strengthened
the association between GI and colorectal cancer risk in the Swedish Mammography Cohort [80],
and higher GL was positively associated with endometrial cancer among nondiabetic women only in
the Iowa Women’s Health Study [81].
Major strengths of the present study are the consideration of many studies and cancer cases, which
provided statistical power to detect moderate associations for most cancer sites, the use of a rigorous
and systematic methodology for identifying and pooling evidence from previous studies, and the
ability to examine GI and GL in association with several types of cancer from cohort and case-control
studies in a single report.
5. Conclusions
The present analysis provides the most comprehensive and updated quantification of the relation
between GI, GL and cancer risk. It indicates moderate unfavorable effects of high versus low GI
on colorectal, and possibly, bladder and kidney cancers, and a possible modest positive association
between GL and endometrial cancer. Such small excess risks may, however, be relevant at the
population level, due to the high incidence of selected cancers, namely colorectal and breast cancer.
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